SEC Company Response from RespireRx Pharmaceuticals Inc. (RSPI) (CIK 0000849636) — Dec 9, 2021
RespireRx Pharmaceuticals Inc. (RSPI) (CIK 0000849636)
Date: Dec. 9, 2021 · CIK: 0000849636 · Accession: 0001493152-21-030958
AI Filing Summary & Sentiment
File numbers found in text: 024-11602
Letter
Re: RespireRx Pharmaceuticals Inc.
December 9, 2021
VIA EDGAR
United States Securities & Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street NE
Washington, D.C. 20549
Offering Statement on Form 1-A, as amended
Filed December 1, 2021
File No. 024-11602
Ladies and Gentlemen:
Pursuant to Rule 252(e) promulgated under the Securities Act of 1933, as amended (the “Act”), RespireRx Pharmaceuticals Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) issue a qualification order for the above referenced Offering Statement on Form 1-A, so that it may be qualified at 4:00 p.m., Eastern Time on Monday, December 13, 2021, or as soon thereafter as is practicable.
We understand that the Commission does not intend to review the above referenced Offering Statement.
The Company acknowledges that the Company and its management are responsible for the accuracy and adequacy of its disclosures, notwithstanding any review, comments, action or absence of action by the staff.
If you have any questions, please contact the undersigned at (201) 444-4947.
Thank you in advance for your assistance.
Sincerely,
RESPIRERX
PHARMACEUTICALS INC.
Show Raw Text
CORRESP
1
filename1.htm
December
9, 2021
VIA
EDGAR
United
States Securities & Exchange Commission
Division
of Corporation Finance
Office
of Life Sciences
100 F Street NE
Washington, D.C. 20549
Re:
RespireRx
Pharmaceuticals Inc.
Offering
Statement on Form 1-A, as amended
Filed
December 1, 2021
File
No. 024-11602
Ladies
and Gentlemen:
Pursuant
to Rule 252(e) promulgated under the Securities Act of 1933, as amended (the “Act”), RespireRx Pharmaceuticals Inc.
(the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”)
issue a qualification order for the above referenced Offering Statement on Form 1-A, so that it may be qualified at 4:00 p.m., Eastern
Time on Monday, December 13, 2021, or as soon thereafter as is practicable.
We
understand that the Commission does not intend to review the above referenced Offering Statement.
The
Company acknowledges that the Company and its management are responsible for the accuracy and adequacy of its disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
If
you have any questions, please contact the undersigned at (201) 444-4947.
Thank
you in advance for your assistance.
Sincerely,
RESPIRERX
PHARMACEUTICALS INC.
By:
/s/
Jeff E. Margolis
Jeff
E. Margolis
SVP,
CFO, Secretary and Treasurer
cc:
Elizabeth A. Diffley
Faegre
Drinker Biddle & Reath LLP
RespireRx
Pharmaceuticals Inc., 126 Valley Road, Suite C, Glen Rock, NJ 07452
www.RespireRx.com